1. Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?

2. Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Treatment Paradigm Newly Diagnosed Transplant-Eligible MM Patients

4. Use of ASCT

5. ASCT Use by Ethnicity

6. Increasingly Stringent Response Criteria

7. IFM 2009 Study Depth of Response

8. Case: Robert

9. Standard Induction Therapy Transplant-Eligible Patients

10. What If Robert Were Older?

11. Cardiac Toxicity With Carfilzomib

12. Age and ASCT

13. How Does Robert's High-Risk Disease Affect Approach to Treatment?

14. High-Risk MM

15. Renal Dysfunction

16. Planning for ASCT

17. Plerixafor Plus G-CSF vs Cyclophosphamide Plus G-CSF

18. "On-Demand" Plerixafor Mobilization

19. Case (cont)

20. IFM 2009 Study Depth of Response

21. Reducing Burdens of Transplant Therapy

22. Case (cont)

23. STaMINA/BMT CTN0702 and EMN02/H095

24. Lenalidomide Maintenance After ASCT Meta-Analysis

25. Long-Term Care Partnership

26. Maintenance Lenalidomide Safety

27. Key Takeaways

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)